《新股消息》內地專業皮膚護理產品公司鉅子生物申請上市 高瓴參投
內地專業皮膚護理產品公司鉅子生物向聯交所提交主板上市申請,聯席保薦人爲高盛及中金公司。
初步招股資料顯示,鉅子生物擁有可復美、可麗金、欣(甘)(SKIGIN)等8大主要品牌,產品組合共有105項SKU,涵蓋功效性護膚品、醫用敷料和功能性食品,目前產品已銷售及經銷至中國1,000多家公立醫院、約1,700傢俬立醫院和診所,以及約300個連鎖藥房品牌。
集團去年度收入錄得15.52億元人民幣,按年增長30.4%,全年利潤8.28億元,按年升近0.2%。
高瓴投資旗下GSUM XV HK於2021年8月與西安鉅子生物簽訂增資協議,持有集團上市前約4%股權。另外,中信產業基金旗下CPE China Fund及中金公司旗下CICC Healthcare亦有參與投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.